Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 6

Economic burden of chronic bronchitis in the United States: a retrospective case-control study

Authors Christopher M Blanchette, Melissa H Roberts, Hans Petersen, et al 

Published 13 January 2011 Volume 2011:6 Pages 73—81

DOI https://doi.org/10.2147/COPD.S15882

Review by Single-blind

Peer reviewer comments 4

Christopher M Blanchette1, Melissa H Roberts1, Hans Petersen1, Anand A Dalal2, Douglas W Mapel3
1Division of Clinical and Outcomes Research, Lovelace Respiratory Research Institute, Kannapolis, NC, USA; 2US Health Outcomes, GlaxoSmithKline, Research Triangle Park, NC, USA; 3Lovelace Clinic Foundation, Albuquerque, NM, USA

Background: Chronic bronchitis (CB) is often misdiagnosed or diagnosed at a later stage of chronic obstructive pulmonary disease (COPD). We examined how this later diagnosis may impact health care costs and utilization during the 12 months prior to and 24 months post initial CB diagnosis.
Methods: This retrospective case-control analysis used claims data from a large US database from July 1, 2003 through June 30, 2007. Patients with CB aged 40 years and older were propensity matched (N = 11,674) to patients without evidence of COPD or asthma by demographics, CB diagnosis quarter/year, and comorbidities. Group differences were assessed using Student's t-test and Pearson chi-square test statistics.
Results: Six months prediagnosis, CB patients had higher frequencies of any hospitalization (9.6%, 6.7%; P < 0.05), emergency department/urgent care visits (13.3%, 6.7%; P < 0.05), and prescriptions (97.3%, 94.1%; P < 0.05). Six months postdiagnosis, CB patients had 5.6 times more hospitalizations (P < 0.05) and 3.1 times more emergency department/urgent care visits (P < 0.05) compared with controls. Mean total costs (US$) for CB patients 12 months prediagnosis were significantly higher than controls (months 12–7: $4212, $3826; P < 0.05; months 6–1: $5289, $4285; P < 0.05). CB patients had higher mean total costs ($8919; P < 0.05) 6 months postdiagnosis. Costs remained $2429 higher for CB patients 19–24 months postdiagnosis (P < 0.05).
Conclusion: Health care costs and utilization among CB patients are increased both prior to diagnosis and during the 2 years postdiagnosis. This study suggests that not accurately diagnosing CB early has a substantial impact on health care costs, and that the economic burden for CB patients remains elevated even after adjustment for comorbidities associated with COPD.

Keywords: chronic bronchitis, burden, economic, chronic obstructive pulmonary disease

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other article by this author:

Readers of this article also read:

Factors associated with good self-rated health and quality of life in subjects with self-reported COPD

Arne M, Lundin F, Boman G, Janson C, Janson S, Emtner M

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:511-519

Published Date: 7 October 2011

Long-term azithromycin therapy in patients with severe COPD and repeated exacerbations

Pomares X, Montón C, Espasa M, Casabon J, Monsó E, Gallego M

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:449-456

Published Date: 6 September 2011

Disability related to COPD tool (DIRECT): towards an assessment of COPD-related disability in routine practice

Aguilaniu B, Gonzalez-Bermejo J, Regnault A, Dias Barbosa C, Arnould B, Mueser M, Granet G, Bonnefoy M, Similowski T

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:387-398

Published Date: 5 July 2011

Tiotropium reduces risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials

Cooper CB, Anzueto A, Decramer M, Celli B, Tashkin DP, Leimer I, Kesten S

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:269-275

Published Date: 9 May 2011

Hypoxemia in patients with COPD: cause, effects, and disease progression

Brian D Kent, Patrick D Mitchell, Walter T McNicholas

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:199-208

Published Date: 14 March 2011